Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.
Abstract: Methods of expanding a natural killer (NK) cell fraction for transplantation into a subject are provided, and particularly, methods for providing transplantable NK cell fractions and protocols for their use, which can be employed for applications in cell transplants and infusions for treatment of cancer and other disease.
Abstract: The invention provides antigen binding domains that bind human leukocyte antigen G (HLA-G) protein comprising the antigen binding domains that bind HLA-G, polynucleotides encoding them, vectors, host cells, methods of making and using them.
Type:
Grant
Filed:
July 29, 2021
Date of Patent:
November 28, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Natasa Obermajer, Adam Zwolak, Sylvie Laquerre, Dirk Brehmer, Desiree De Lange, Julien Häsler, Shana Versmissen, Theodore D. Petley, Kelly van de Ven, Fang Yi, Sanjaya Singh, Rajkumar Ganesan
Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
November 21, 2023
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Nai-Kong V. Cheung, Andres Lopez-Albaitero, Hong Xu
Abstract: The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a curcumin molecule or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent. In another embodiment, the present invention provides a method of treating cancer by administering a therapeutically effective amount of a composition comprising a micelle construct attached to curcumin or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent.
Abstract: An anti-HGFR antibody fragment in combination with an extracellular portion of human HGFR for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein: (i) the anti-HGFR antibody fragment has only one paratope able to bind to an epitope of the extracellular portion of human HGFR and has antagonist activity towards HGFR, (ii) the extracellular portion of human HGFR is capable of binding to HGF in a stable manner and contains at least one amino acid mutation at the epitope recognized by the anti-HGFR antibody fragment to prevent binding of the anti-HGFR antibody fragment thereto, and (iii) the anti-HGFR antibody fragment and the extracellular portion of human HGFR are suitable for administration to the patient are suitable for administration to the patient (a) in a protein form or (b) in a nucleic acid form.
Type:
Grant
Filed:
March 21, 2019
Date of Patent:
November 14, 2023
Assignee:
Vertical Bio AG
Inventors:
Cristina Basilico, Elisa Vigna, Paolo Maria Comoglio
Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
Abstract: A system for generating a model for predicting a molecular property of a variant of a molecule is provided. For each of a plurality of variants of the molecule, the system for each structural feature, aggregates the values for the structural features of the residues of the molecule that were modified to form the variant to form a feature vector for the variant. The system assigns the value for the molecular property of the variant to the feature vector wherein the feature vector and the assigned value form training data. The system then generates the model for predicting a value for the molecular property using the training data for the plurality of variants.
Type:
Grant
Filed:
June 8, 2018
Date of Patent:
October 31, 2023
Assignee:
Just-Evotec Biologics, Inc.
Inventors:
Jeremy Martin Shaver, Randal Robert Ketchem
Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.
Type:
Grant
Filed:
August 9, 2018
Date of Patent:
October 31, 2023
Assignees:
PamGene B.V., Erasmus University Medical Center Rotterdam
Inventors:
Robby Ruijtenbeek, Dirgje Maria Adriana Van Den Heuvel, Richard De Wijn, Joan Gertrudis Jacobus Victor Aerts, Adrianus Henricus Josephus Mathijssen
Abstract: Disclosed herein are methods for the treatment of an individual having an inflammatory bowel disease (“IBD”). The disclosed methods may include the detection of Oncostatin M (OSM) in a biological sample obtained from an individual having an IBD. The detection of OSM may be used to characterize the individual as a tumor necrosis factor (TNF) inhibitor (TNFi) responder or a TNFi non-responder for selection of appropriate treatment.
Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
October 10, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
October 10, 2023
Assignee:
Cancer Research Technology Limited
Inventors:
Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
Abstract: HER3 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the HER3 antigen-binding molecules.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
October 10, 2023
Assignee:
Hummingbird Bioscience Pte. Ltd.
Inventors:
Jerome Douglas Boyd-Kirkup, Piers Ingram, Dipti Thakkar, Zhihao Wu, Konrad Paszkiewicz, Vicente Sancenon, Siyu Guan
Abstract: The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
October 3, 2023
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: NEO-201 is a humanized IgG1 monoclonal antibody (mAb) that is highly reactive against the majority of tumor tissues from many different carcinomas, including colon, pancreatic, stomach, lung, breast, and uterine cancers, but the overwhelming majority of normal tissues are not recognized by this antibody. Functional assays revealed that NEO-201 is capable of mediating both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells. Furthermore, the growth of human pancreatic xenograft tumors in vivo was largely attenuated by treatment with NEO-201 both alone and in combination with human peripheral blood mononuclear cells (PBMC) as an effector cell source for ADCC. In vivo biodistribution studies in human tumor xenograft-bearing mice revealed that NEO-201 preferentially accumulates in the tumor but not organ tissue.
Abstract: This document provides methods and materials involved in identifying mammals (e.g., humans) having cancer cells with an elevated level of phosphorylated Ub polypeptides (e.g., an elevated level of Y59 phosphorylated Ub polypeptides). For example, methods and materials for detecting the presence of cancer cells having an elevated level of Y59 phosphorylated Ub polypeptides are provided.
Type:
Grant
Filed:
November 6, 2018
Date of Patent:
September 26, 2023
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases.
Abstract: The present disclosure relates to an isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1. Also provided is the pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.
Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.
Abstract: An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.
Type:
Grant
Filed:
July 13, 2020
Date of Patent:
August 29, 2023
Assignee:
Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.